Phenserine regulates translation of beta -amyloid precursor protein mRNA by a putative interleukin-1 responsive element, a target for drug development
about
Alzheimer's disease therapeutics targeted to the control of amyloid precursor protein translation: maintenance of brain iron homeostasisRivastigmine lowers Aβ and increases sAPPα levels, which parallel elevated synaptic markers and metabolic activity in degenerating primary rat neuronsAge-dependent neuroplasticity mechanisms in Alzheimer Tg2576 mice following modulation of brain amyloid-β levelsNovel 5' untranslated region directed blockers of iron-regulatory protein-1 dependent amyloid precursor protein translation: implications for down syndrome and Alzheimer's disease(-)-Phenserine attenuates soman-induced neuropathologyCognitive Impairments Induced by Concussive Mild Traumatic Brain Injury in Mouse Are Ameliorated by Treatment with Phenserine via Multiple Non-Cholinergic and Cholinergic MechanismsSelective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer beta-amyloid peptide in rodentSynthesis of the Alzheimer drug Posiphen into its primary metabolic products (+)-N1-norPosiphen, (+)-N8-norPosiphen and (+)-N1, N8-bisnorPosiphen, their inhibition of amyloid precursor protein, α-Synuclein synthesis, interleukin-1β release, and cholA synopsis on the role of tyrosine hydroxylase in Parkinson's diseasePhysiological and pathological aspects of Abeta in iron homeostasis via 5'UTR in the APP mRNA and the therapeutic use of iron-chelators.Changing the course of Alzheimer's disease: anti-amyloid disease-modifying treatments on the horizon.Heterologous amyloid seeding: revisiting the role of acetylcholinesterase in Alzheimer's disease.The alpha-synuclein 5'untranslated region targeted translation blockers: anti-alpha synuclein efficacy of cardiac glycosides and Posiphen.Using BAC transgenesis in zebrafish to identify regulatory sequences of the amyloid precursor protein gene in humans.Neurotrophic and neuroprotective actions of (-)- and (+)-phenserine, candidate drugs for Alzheimer's disease.Modulation of amyloid precursor protein expression reduces β-amyloid deposition in a mouse model.Multifunctional neuroprotective derivatives of rasagiline as anti-Alzheimer's disease drugsDonepezil in Alzheimer's disease: From conventional trials to pharmacogeneticsNeurobiology of butyrylcholinesterase.Future directions in the treatment of Alzheimer's disease.Biochemical differentiation of cholinesterases from normal and Alzheimer's disease cortex.Modulation of human neural stem cell differentiation in Alzheimer (APP23) transgenic mice by phenserine.Interactions between beta-amyloid and central cholinergic neurons: implications for Alzheimer's disease.The anticholinesterase phenserine and its enantiomer posiphen as 5'untranslated-region-directed translation blockers of the Parkinson's alpha synuclein expressionPosiphen as a candidate drug to lower CSF amyloid precursor protein, amyloid-β peptide and τ levels: target engagement, tolerability and pharmacokinetics in humans.Cholinergic and glutamatergic drugs in Alzheimer's disease therapy.Acetylcholinesterase inhibitors for the treatment of dementia in Alzheimer's disease: do we need new inhibitors?Novel cholinesterase inhibitors as future effective drugs for the treatment of Alzheimer's disease.Role of acetylcholinesterase inhibitors in pharmacological regulation of amyloid precursor protein processing.Targeting acetylcholinesterase to treat neurodegeneration.Phenserine.Context dependent function of APPb enhancer identified using enhancer trap-containing BACs as transgenes in zebrafish.Cholinesterase inhibitors improve both memory and complex learning in aged beagle dogs.Physiological and pathological role of alpha-synuclein in Parkinson's disease through iron mediated oxidative stress; the role of a putative iron-responsive elementPharmacological Treatment of Alzheimer's Disease: Is it Progressing Adequately?Phenserine efficacy in Alzheimer's disease.Fire in the ashes: can failed Alzheimer's disease drugs succeed with second chances?Was phenserine a failure or were investigators mislead by methods?New pharmacological approaches to the cholinergic system: an overview on muscarinic receptor ligands and cholinesterase inhibitors.Status of acetylcholinesterase and butyrylcholinesterase in Alzheimer's disease and type 2 diabetes mellitus.
P2860
Q27024824-CE19422F-0328-4F4C-90A4-01276FBBE1DBQ28479242-0C952C33-51DD-4F97-8B51-9245F84423A1Q28488088-A683728D-96C0-4B97-9EB3-FB8973F85FE7Q28535011-875F8A87-AE71-424F-B210-07BA6AA52E4AQ28539914-F8B4A611-0E31-469C-B2F1-4E5103074B58Q28552599-8DA8AE64-A2B5-4560-A0F6-DCC46DBDFA9BQ28578059-CBAF00EC-19FF-4CBA-93CF-E0562E8FF357Q28818062-FD6AA069-718D-4C43-BD25-71A9127291C6Q28830946-3A10E361-D23C-4641-A231-C5E2E31AC5DAQ30855088-070E1854-C4AA-4F04-862B-276FAC34AFA4Q33289262-F561BAEF-C9A4-4E76-879D-34A80170786CQ33291757-6C926870-9DB8-4EF6-8CA5-8CAC1ABBD305Q33790013-206D0888-6C31-448F-875E-13AF31C8C7FFQ34402725-08083FFF-4027-4B82-949D-28811E522FCCQ34575780-049E98DC-1B00-427D-A154-40DD56F513D1Q34584517-3EB8E0BF-2B7F-428F-A9BD-18200720C231Q34911093-A90A80CD-349F-418E-BEE1-F57BA5A073F1Q34965949-EBE212FD-21BE-4841-B034-D8B04A5A2AC6Q35058510-25D78E01-AEFE-454D-A41A-80B00F4D1366Q35753450-1C723066-F7FF-4D8B-9D98-0CDFC0B851C7Q35757336-B736CF20-1F26-49BD-8D55-470CA47AE045Q35927997-5A34AED8-BB62-45BF-97E9-2B923D273B90Q36006524-3A025B30-5E22-4A91-BD39-D93CED6E3FDDQ36012226-51EE838A-F98A-46CE-BCB6-FA536363AFC5Q36152393-69640EDC-7E0D-4824-A5F1-7AA75143785CQ36257227-567126EA-926A-47E8-A2FB-103F95261919Q36302845-71A9F86E-5113-4E66-B036-17691C7B4B48Q36349629-0520DB35-AEF1-4DE7-BCF3-132CD6CF87D0Q36479863-1C6CEA21-051E-4205-A273-25D35E489902Q36709537-39CB0908-C79B-42F1-AD40-F1FC4436B63BQ36861622-DF1D7A2A-3318-48A7-A8A7-1B507089F55AQ36959624-B1F42271-E04E-4CE1-8692-212441F76186Q37163279-F72B585F-28B9-4D49-87FD-E8E8BC14DC6AQ37166339-B2B4DCCA-D18D-47EF-9ED3-D4BB25DCE7B4Q37198579-80A83B35-DEFA-4154-A38E-11303F6FB580Q37510264-1E78E64A-79DC-4FAB-9585-E0602569FA7CQ37524877-1346F7C0-7F46-4AE7-9C43-1E7AC66DF710Q37530878-B0914401-C228-47C1-9B5F-3BD992A81460Q38099889-90A5CC7D-7316-44AC-9E52-58D8D0874307Q38262767-F815E38D-8610-43E0-A633-4CB919F964DF
P2860
Phenserine regulates translation of beta -amyloid precursor protein mRNA by a putative interleukin-1 responsive element, a target for drug development
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh
2001年學術文章
@zh-hant
name
Phenserine regulates translati ...... a target for drug development
@ast
Phenserine regulates translati ...... a target for drug development
@en
type
label
Phenserine regulates translati ...... a target for drug development
@ast
Phenserine regulates translati ...... a target for drug development
@en
prefLabel
Phenserine regulates translati ...... a target for drug development
@ast
Phenserine regulates translati ...... a target for drug development
@en
P2093
P2860
P356
P1476
Phenserine regulates translati ...... a target for drug development
@en
P2093
D K Lahiri
K Sambamurti
P2860
P304
P356
10.1073/PNAS.131152998
P407
P577
2001-06-12T00:00:00Z